Skip to main content
$5.67 $0.16 (2.9%)

04:00 PM EST on 12/07/23

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

CAPS Rating: 2 out of 5

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

Current Price $5.67 Mkt Cap $1.2B
Open $5.54 P/E Ratio -4.52
Prev. Close $5.67 Div. (Yield) $0.00 (0.0%)
Daily Range $5.42 - $6.00 Volume 9,863,925
52-Wk Range $4.83 - $12.08 Avg. Daily Vol. 3,348,745

Caps

How do you think NASDAQ:BCRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

256 Outperform
81 Underperform
 

All-Star Players

29 Outperform
30 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BCRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

VladimirPoutine (< 20)
Submitted February 06, 2022

Already profitable; growing; good pipeline

zzlangerhans (98.80)
Submitted April 01, 2013

As I predicted, BioCryst still had a little life left which allowed me to escape my green thumb and flip turn into a red one. 33% jump today, and all because of this:BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary… More

Recent Community Commentary

Read the most recent pitches from players about BCRX.

Recs

1
Member Avatar VladimirPoutine (< 20) Submitted: 2/6/2022 2:45:41 PM : Outperform Start Price: $14.89 NASDAQ:BCRX Score: -63.86

Already profitable; growing; good pipeline

Recs

1
Member Avatar PensionExtender (< 20) Submitted: 6/30/2020 5:50:50 PM : Outperform Start Price: $4.90 NASDAQ:BCRX Score: -32.26

COVID-19 biotech should continue to grow with oral delivery system of vaccine

Recs

1
Member Avatar mdriver78 (66.02) Submitted: 5/8/2020 1:14:04 PM : Outperform Start Price: $4.36 NASDAQ:BCRX Score: -22.26

Expecting positive sales of over $500 on Berotralstat approval. Plus early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases plus patient dosing underway in galidesivir trial in COVID-19 patients in Brazil. All sounds quite positive and worth a flyer.

Leaderboard

Find the members with the highest scoring picks in BCRX.

Score Leader

Chemnerd

Chemnerd (32.58) Score: +564.96

The Score Leader is the player with the highest score across all their picks in BCRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
KeepYourCoolFool 94.02 7/29/2009 Underperform 5Y $10.58 -46.41% +371.91% +418.32 0 Comment
DRASH5 36.03 7/29/2009 Underperform 3W $10.28 -44.84% +373.37% +418.21 0 Comment
WeathermanGR13 91.84 8/17/2009 Underperform 5Y $9.88 -42.61% +365.79% +408.40 0 Comment
BASSTRAX 58.91 8/31/2009 Underperform 1Y $12.99 -56.35% +351.45% +407.80 0 Comment
SpencerHar 43.01 8/3/2009 Underperform 1Y $9.10 -37.69% +360.98% +398.68 0 Comment
BadB0y4Lyfe 23.64 8/10/2009 Underperform 5Y $9.27 -38.83% +357.04% +395.87 0 Comment
epc53 78.99 7/20/2009 Underperform 5Y $6.00 -5.50% +386.28% +391.78 0 Comment
clutedog 88.62 4/30/2009 Underperform 1Y $3.88 +46.13% +426.73% +380.60 1 Comment
1or5stars 98.78 5/26/2009 Underperform 3W $3.85 +47.27% +423.99% +376.72 0 Comment
mathieugp 55.97 10/1/2009 Underperform 3W $8.65 -34.45% +335.00% +369.45 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BCRX.